Gerilimzumab

杰瑞单抗

Report date: 2022/06/27 20:00:35

Base Information

Drug NameGerilimzumab
Drug Alias NameGB-224RYI-008ARGX-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 modulators
TargetsInterleukin-6
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesArgenx Se
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEdding Genor Group Holdings LtdShanghai Ruiyi Medical Technology Co LtdArgenx Se +[4] 
Inactive CompaniesBird Rock Bio Inc
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A